IRON
Bearish signalScored 2026-09-17 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Disc Medicine, Inc.
- Nom
- Disc Medicine, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.9B
- Employés
- 165
- PDG
- John D. Quisel
- Site web
- https://www.discmedicine.com
- Marché
- AGIOCOAGDMRAGERNPTGX
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 60 136 titres (~4 480 006,26 $ US)
- Insiders
- Bitterman KevinQuisel John D
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,079,963
Avg sell (VWAP, 90d window) $75.56 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$2,177,458 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-11
- Last synced
-
2026-09-17 09:54:31
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-11 | Bitterman Kevin | Sell · S | 27,136 | $70.11 | $1,902,505 | Form 4 |
| 2026-09-04 | Bitterman Kevin | Sell · S · 10b5-1 | 18 | $79.96 | $1,439 | Form 4 |
| 2026-09-03 | Bitterman Kevin | Sell · S · 10b5-1 | 54 | $79.98 | $4,319 | Form 4 |
| 2026-09-02 | Bitterman Kevin | Sell · S · 10b5-1 | 2 | $80.98 | $162 | Form 4 |
| 2026-09-01 | Bitterman Kevin | Sell · S · 10b5-1 | 1 | $79.95 | $80 | Form 4 |
| 2026-08-25 | Yu Jonathan Yen-Wen | Sell · S · 10b5-1 | 8,796 | $83.12 | $731,092 | Form 4 |
| 2026-08-24 | Yu Jonathan Yen-Wen | Sell · S · 10b5-1 | 300 | $82.53 | $24,760 | Form 4 |
| 2026-08-17 | Quisel John D | Sell · S · 10b5-1 | 11,888 | $79.84 | $949,162 | Form 4 |
| 2026-08-12 | Yu Jonathan Yen-Wen | Sell · S · 10b5-1 | 804 | $82.64 | $66,445 | Form 4 |
| 2026-08-06 | Khara Rahul | Sell · S · 10b5-1 | 5,000 | $80.00 | $400,000 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-17 Drivers: fundamentals. Moteurs : fondamentaux.
IRON presents a deeply unfavorable risk/reward profile: despite adequate liquidity (score 85), the company generates zero revenue, burns cash persistently, and shows no viable path to profitability (fundamental trend…
The first sentence of the analysis written for IRON on 2026-09-17 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 21.94 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 21.940 | 21.171 | 17.056 | 8.791 | 6.740 | |
| Quick Ratio | 21.940 | 21.171 | 17.056 | 8.791 | 6.740 | |
| Solvency Ratio | -3.160 | -2.053 | -3.337 | -1.980 | -0.229 | |
| Cash Ratio | 2.488 | 8.253 | 16.810 | 8.619 | 6.558 | |
| Price To Earnings Ratio | -13.213 | -16.010 | -16.889 | -0.442 | -0.648 | |
| Price To Earnings Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Forward Price To Earnings Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Price To Earnings Diluted Ratio | -13.213 | -16.010 | -16.889 | -0.442 | -0.648 | |
| Price To Earnings Diluted Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Price To Book Ratio | 3.788 | 3.946 | 3.735 | 0.117 | -0.363 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.457 | -18.534 | -17.525 | -0.488 | -0.845 | |
| Price To Operating Cash Flow Ratio | -15.537 | -18.634 | -17.546 | -0.489 | -0.847 | |
| Debt To Assets Ratio | 0.002 | 0.060 | 0.006 | 0.007 | 0.076 | |
| Debt To Equity Ratio | 0.003 | 0.068 | 0.006 | 0.008 | -0.110 | |
| Debt To Capital Ratio | 0.003 | 0.063 | 0.006 | 0.007 | -0.123 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.060 | 0.000 | 0.000 | -0.006 | |
| Financial Leverage Ratio | 1.091 | 1.120 | 1.066 | 1.134 | -1.439 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.923 | -4.028 | -3.427 | -1.871 | -2.051 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.005 | 1.001 | 1.004 | 1.002 | |
| Debt Service Coverage Ratio | -49.383 | -189.911 | 0.000 | 0.000 | -4.719 | |
| Interest Coverage Ratio | -65.434 | -226.783 | 0.000 | 0.000 | -14.334 | |
| Short Term Operating Cash Flow Coverage Ratio | -295.242 | 0.000 | 0.000 | 0.000 | -5.507 | |
| Operating Cash Flow Coverage Ratio | -96.777 | -3.131 | -34.965 | -31.673 | -3.902 | |
| Capital Expenditure Coverage Ratio | -193.347 | -185.992 | -825.416 | -279.815 | -404.912 | |
| Dividend Paid And Capex Coverage Ratio | -193.347 | -185.992 | -825.416 | -279.815 | -404.912 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.050 | -14.665 | -12.209 | 3.693 | 1.707 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 21.940 | ▲0.769 | ▲6.800 |
| Quick Ratio | 21.940 | ▲0.769 | ▲6.800 |
| Solvency Ratio | -3.160 | ▼-1.107 | ▼-1.008 |
| Cash Ratio | 2.487 | ▼-5.766 | ▼-6.058 |
| Price To Earnings Ratio | -13.213 | ▲2.797 | ▼-3.773 |
| Price To Earnings Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Forward Price To Earnings Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Price To Earnings Diluted Ratio | -13.213 | ▲2.797 | ▼-3.773 |
| Price To Earnings Diluted Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Price To Book Ratio | 3.788 | ▼-0.157 | ▲1.544 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -15.457 | ▲3.077 | ▼-4.888 |
| Price To Operating Cash Flow Ratio | -15.537 | ▲3.097 | ▼-4.927 |
| Debt To Assets Ratio | 0.002 | ▼-0.058 | ▼-0.028 |
| Debt To Equity Ratio | 0.003 | ▼-0.065 | ▲0.008 |
| Debt To Capital Ratio | 0.003 | ▼-0.061 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.002 | ▼-0.058 | ▼-0.009 |
| Financial Leverage Ratio | 1.091 | ▼-0.029 | ▲0.496 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.923 | ▼-0.895 | ▼-1.663 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▼-0.000 | ▲0.002 |
| Debt Service Coverage Ratio | -49.383 | ▲140.528 | ▼-0.580 |
| Interest Coverage Ratio | -65.434 | ▲161.349 | ▼-4.124 |
| Short Term Operating Cash Flow Coverage Ratio | -295.242 | ▼-295.242 | ▼-235.092 |
| Operating Cash Flow Coverage Ratio | -96.777 | ▼-93.647 | ▼-62.688 |
| Capital Expenditure Coverage Ratio | -193.347 | ▼-7.355 | ▲184.549 |
| Dividend Paid And Capex Coverage Ratio | -193.347 | ▼-7.355 | ▲184.549 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.050 | ▲1.615 | ▼-6.145 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.80B | $1.75B | $1.29B | $20.7M | $23.3M | |
| Enterprise value | $2.71B | $1.59B | $930.7M | -$172.6M | -$57.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.04x | -16.91x | -12.67x | 4.08x | 2.09x | |
| EV / Free cash flow | -14.96x | -16.81x | -12.65x | 4.07x | 2.09x | |
| EV / EBITDA | -13.05x | -14.66x | -12.21x | 3.69x | 1.71x | |
| Net debt / EBITDA | 0.43x | 1.50x | 4.70x | 4.13x | 2.40x | |
| Current ratio | 21.94x | 21.17x | 17.06x | 8.79x | 6.74x | |
| Income quality | 0.85x | 0.86x | 0.96x | 0.90x | 0.77x | |
| Graham net-net | $21 | $16 | $15 | $165 | -$86 | |
| Tax burden | 100.2% | 100.3% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 101.7% | 100.5% | 100.0% | 100.0% | 106.4% | |
| Working capital | $767.3M | $470.3M | $344.2M | $175.9M | $77.1M | |
| Invested capital | $769.5M | $472.6M | $346.3M | $177.5M | $78.8M | |
| Return on assets | -26.3% | -22.0% | -20.8% | -23.4% | -38.9% | |
| Operating ROA | -36.2% | -30.0% | -32.1% | -32.4% | -61.4% | |
| Return on tangible assets | -26.3% | -22.0% | -20.8% | -23.4% | -38.9% | |
| Return on equity | -28.7% | -24.7% | -22.1% | -26.5% | 56.0% | |
| Return on invested capital | -30.6% | -27.4% | -26.2% | -26.7% | -36.7% | |
| Return on capital employed | -30.6% | -27.4% | -26.3% | -26.7% | -39.2% | |
| Earnings yield | -7.6% | -6.2% | -5.9% | -226.5% | -154.2% | |
| Free cash flow yield | -6.5% | -5.4% | -5.7% | -205.1% | -118.3% | |
| Capex / Op. cash flow | -0.5% | -0.5% | -0.1% | -0.4% | -0.2% | |
| Capex / Depreciation | 332.0% | 323.7% | 89.0% | 169.7% | 212.5% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+60.1%EV / Sales n/aEV / EBITDA ▲+11.0%EV / Op. cash flow ▲+1.862Earnings yield ▼-0.013
Profitability
Return on equity ▼-0.040Return on assets ▼-0.043Return on invested capital ▼-0.032Return on capital employed ▼-0.032Operating ROA ▼-0.062Income quality ▼-0.009Tax burden ▼-0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.769Net debt / EBITDA ▼-1.071Working capital ▲+296958000.000Invested capital ▲+296893000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+11917.6%EV / Sales n/aEV / EBITDA ▼-864.6%EV / Op. cash flow ▼-17.136Earnings yield ▲+1.467
Profitability
Return on equity ▼-0.847Return on assets ▲+0.126Return on invested capital ▲+0.061Return on capital employed ▲+0.085Operating ROA ▲+0.252Income quality ▲+0.085Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+15.199Net debt / EBITDA ▼-1.968Working capital ▲+690197000.000Invested capital ▲+690705000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-09-15 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-09-14 Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-12 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-09-11 Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-09-09 Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV). The data, presented in a poster session at the 2026 Society of Hematologic Oncology (SOHO) annual meeting in Houston, TX, demonstrated that treatment with DISC-3405 increased hepcidin and lowered serum iron, translating to reduction in phlebotomy, controlled hematocrit, and improved symptom burden in patients with PV. These data will be featured in an oral presentation at the SOHO conference tomorrow, September 10. Disc also presented an encore of the positive results from the Phase 2 RALLY-MF trial of selcodebart (DISC-0974) in patients with anemia of myelofibrosis (MF) and a new systematic literature review characterizing the humanistic burden of anemia associated with MF through patient reported outcomes.
- 2026-09-09 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-09-08 ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-09-07 IRON, the World''s First Advanced General-Purpose Humanoid Robot, Walks off the Production Lines as XPENG''s Humanoid Robot Manufacturing Facility Is Officially Commissioned XPENG has officially commissioned its humanoid robot production lines and completed the production-lines manufacturing of the world''s first advanced humanoid robot, which autonomously walked off the lines, marking a critical leap from R&D prototyping to production-lines manufacturing. XPENG''s humanoid robot production lines feature core process automation exceeding 80%, setting a new manufacturing benchmark with a precision, flexible, and intelligent production line.
- 2026-09-04 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-09-02 ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - September 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.